Loading clinical trials...

Your health journey, clearly organized.

Legal

A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma | Clinical Trials | Clareo Health

Back to search

COMPLETEDPhase 2

A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma

NCT02086175•Dana-Farber Cancer Institute

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas

Interventions

Imprime PGG

Rituximab

Locations

United States

Locations (1)

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Key Dates

Start Date

December 1, 2014

Primary Completion Date

July 11, 2019

Completion Date

February 1, 2021

Last Updated

April 6, 2026

Sponsors

Lead Sponsor

Dana-Farber Cancer Institute

Collaborators

HiberCell, Inc.

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 6, 2026Data synced to Clareo: April 27, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions